Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigalimab dose selection from monotherapy dose escalation...

Descripción completa

Detalles Bibliográficos
Autores principales: Powderly, John, Spira, Alexander, Kondo, Shunsuke, Doi, Toshihiko, Luke, Jason J., Rasco, Drew, Gao, Bo, Tanner, Minna, Cassier, Philippe A., Gazzah, Anas, Italiano, Antoine, Tosi, Diego, Afar, Daniel E., Parikh, Apurvasena, Engelhardt, Benjamin, Englert, Stefan, Lambert, Stacie L., Kasichayanula, Sreeneeranj, Mensing, Sven, Menon, Rajeev, Vosganian, Gregory, Tolcher, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877859/
https://www.ncbi.nlm.nih.gov/pubmed/32770720
http://dx.doi.org/10.1111/cts.12855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877859/
https://www.ncbi.nlm.nih.gov/pubmed/32770720
http://dx.doi.org/10.1111/cts.12855

Ejemplares similares